Buffett-Style Value Investment Analysis: Bristol-Myers Squibb (BMY)

---

1️⃣ Circle of Competence Analysis

1.1 Is the Company's Business Easy to Understand?

Business Nature

Bristol-Myers Squibb (BMS) is a global biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, and sale of innovative medicines for serious diseases .

The company operates in a single segment focused on biopharmaceutical products across oncology, hematology, immunology, cardiovascular, and neuroscience .

Core Products (2024–2025 Growth Portfolio) Major products include:

• Opdivo (PD-1 inhibitor, oncology)
• Eliquis (Factor Xa inhibitor, cardiovascular)
• Orencia
• Yervoy
• Reblozyl
• Breyanzi (CAR-T)
• Camzyos
• Sotyktu
• Abecma
• Zeposia

These products are prescription medicines protected by patents and regulatory exclusivity.

Customers

BMS primarily sells to:

• Wholesalers
• Specialty pharmacies
• Hospitals
• Government agencies

Revenue mix (2025):

• United States: 69%
• International: 29%
• Total Revenue: $48.2B

Revenue sources are straightforward: drug sales + royalties + alliance revenue.

Industry

Pharmaceutical industry — highly regulated but structurally understandable:

• Heavy R&D
• Patent-based exclusivity
• Long product cycles
• Binary drug approval risk

📌 Conclusion: The business model is clear and within a traditional Buffett-style circle of competence for large pharma.

---

1.2 Is the Company's Business Logic Clear for the Next 10 Years?

Industry Stage & Size

• Global pharma market > $1.5T.
• Oncology & immunology remain structural growth categories.
• Aging demographics support cardiovascular & oncology demand.

Growth Challenges

However, BMS faces:

• Patent cliffs (Revlimid already declining).
• Eliquis patent expiry risk late decade.
• Opdivo LOE later 2028–2030.

Strategic Moves

2024–2025 acquisitions:

• Karuna (neuroscience)
• RayzeBio (radiopharma)
• Mirati (oncology)

This shows aggressive pipeline replenishment.

Predictability

Short-term cash flows: predictable Long-term (10 yrs): moderate uncertainty due to:

• Patent cliffs
• Drug pipeline execution risk

📌 Conclusion (Circle of Competence): ✅ IN Circle — but requires monitoring patent transitions.

---

2️⃣ Durable Competitive Advantage (Moat)

2.1 Brand & Pricing Power

Pharma brands carry pricing power due to:

• Clinical data
• Regulatory approvals
• Physician trust

Gross margins historically ~70%+ (typical for innovative pharma).

Premium pricing sustained in oncology.

---

2.2 Cost Advantage

Scale advantages:

• Global manufacturing footprint (US, Puerto Rico, Switzerland, Ireland, Netherlands)
• Large R&D platform

However, pharma is innovation-driven, not cost-driven.

Cost advantage = moderate.

---

2.3 Switching Costs

Very high:

• Once patient stabilized on drug, switching risk.
• Oncology regimens embedded in clinical guidelines.

Switching cost = strong moat contributor.

---

2.4 Network Effect

❌ None (not platform-based)

---

2.5 Scale Advantage

Yes:

• $48B revenue scale
• Large global trials capability
• Deep regulatory experience

Scale is difficult to replicate.

📌 Overall Moat: MEDIUM to STRONG

Strong in:

• Intellectual property
• Switching cost
• Regulatory barriers

Weaker in:

• Patent expiration cyclicality

---

3️⃣ Management

3.1 Integrity

• Clean filings.
• SOX 404 internal controls confirmed effective .
• No recent accounting scandals.

---

3.2 Execution

Revenue trend:

• 2022: $46.2B
• 2023: $45.0B
• 2024: $48.3B
• 2025: $48.2B

Flat growth due to LOE impact — but stabilized in 2024–2025.

Acquisition strategy aggressive but pipeline-focused.

---

3.3 Alignment

• Shares outstanding ~2.03B (2025)
• No major dilution.
• Strong dividend history.

📌 Overall Management Rating: GOOD (Disciplined but aggressive in M&A)

---

4️⃣ Financials

4.1 Profitability

Pharma typical margins:

• Gross margin ~70%+
• Operating margin cyclical due to R&D & acquisition amortization
• Net margin pressured by acquisitions

---

4.2 Returns

ROE historically mid-teens. ROIC fluctuates due to large goodwill from Celgene deal.

Above cost of capital but not elite.

---

4.3 Free Cash Flow

Historically strong FCF generation. CapEx light relative to revenue. Cash flows stable.

---

4.4 Capital Structure

• Large debt load from Celgene acquisition.
• Still investment-grade.
• Strong liquidity.

---

4.5 Shareholder Returns

• Dividend yield typically 4%+.
• Moderate buybacks.

📌 Overall Financial Assessment: STRONG CASH GENERATOR, but leveraged

---

5️⃣ Intrinsic Value

(The following content is exclusive to subscribers.)